Search research articles
Contact Us
Filters
Showing results (341-350 of 385) with videos related to
Page
of 39
Sort By:
Hemasphere
|
March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA
Katrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2013
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation
Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, et al.
Blood
|
August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
Haematologica
|
November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Heinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial
Markus Schaich, Stefani Parmentier, Michael Kramer, et al.
Blood
|
February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphology
David W Scott, Rebecca L King, Annette M Staiger, et al.
Cancers
|
August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis
Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Blood
|
August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
German Ott, Marita Ziepert, Wolfram Klapper, et al.
Annals of Hematology
|
March 20, 2016
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Alois Gratwohl, Simona Iacobelli, Natalia Bootsman, et al.
Page
of 39
Search research articles
Search
Showing results (341-350 of 385) with videos related to
Sort By:
Page
of 39
Hemasphere
|
March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA
Katrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2013
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation
Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, et al.
Blood
|
August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
Haematologica
|
November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Heinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial
Markus Schaich, Stefani Parmentier, Michael Kramer, et al.
Blood
|
February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphology
David W Scott, Rebecca L King, Annette M Staiger, et al.
Cancers
|
August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis
Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Blood
|
August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
German Ott, Marita Ziepert, Wolfram Klapper, et al.
Annals of Hematology
|
March 20, 2016
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Alois Gratwohl, Simona Iacobelli, Natalia Bootsman, et al.
Page
of 39